329 related articles for article (PubMed ID: 33797691)
1. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.
Nastoupil LJ
Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691
[TBL] [Abstract][Full Text] [Related]
2. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
3. Refining the management of relapsed or refractory follicular lymphoma.
Pagel JM; Burke JM; Leslie LA
Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
[TBL] [Abstract][Full Text] [Related]
5. Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.
Mondello P; Ansell SM
Expert Opin Pharmacother; 2022 Feb; 23(3):295-301. PubMed ID: 34904909
[TBL] [Abstract][Full Text] [Related]
6. Follicular Lymphoma: a Focus on Current and Emerging Therapies.
Cahill KE; Smith SM
Oncology (Williston Park); 2022 Feb; 36(2):97-106. PubMed ID: 35180337
[TBL] [Abstract][Full Text] [Related]
7. [INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].
Kwiatek M; Pruchniewski Ł; Kwiatek J; Kaźmierczak M; Lewandowski K
Wiad Lek; 2018; 71(5):1095-1098. PubMed ID: 30176648
[TBL] [Abstract][Full Text] [Related]
8. Follicular lymphoma: The long and winding road leading to your cure?
Gordon MJ; Smith MR; Nastoupil LJ
Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
[TBL] [Abstract][Full Text] [Related]
10. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
[TBL] [Abstract][Full Text] [Related]
11. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapies for Follicular Lymphoma.
Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
[TBL] [Abstract][Full Text] [Related]
13. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
[TBL] [Abstract][Full Text] [Related]
14. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.
Hanel W; Epperla N
J Hematol Oncol; 2021 Jun; 14(1):104. PubMed ID: 34193230
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
16. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
[TBL] [Abstract][Full Text] [Related]
17. A closer look at tazemetostat.
Batlevi CL
Clin Adv Hematol Oncol; 2020 Dec; 18(12):820-822. PubMed ID: 33406058
[No Abstract] [Full Text] [Related]
18. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
19. [Standard treatment and future perspectives for follicular lymphoma].
Kameoka Y
Rinsho Ketsueki; 2022; 63(9):1135-1144. PubMed ID: 36198539
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
